KT

Kenan Turnacioglu

Chair of B.O.D at Paige

New York City Metropolitan Area

Overview

Work Experience

  • Board Member

    2022 - Current

  • Board Member

    2020

  • Member Board Of Directors

    2020 - 2022

  • Board Member

    2020 - 2022

  • Chair Of The Board Of Directors

    2017

    · Company spun out of Memorial Sloan Kettering with goal of applying machine · Learning/artificial intelligence to supplement the pathologist in diagnosis.

  • General Partner & Member of the Investment Committee

    2020 - 2021

    Catalio Capital Management invests in breakthrough biomedical technologies companies around the globe.

  • Founding Partner

    2011 - 2018

    · Founding Partner of Firm that was launched with $4.25bn in assets and grew to $10bn · Managed on average $2bn in capital in Healthcare, Consumer, and TMT · Oversaw the development of the firms Technology and Media group · Oversaw the development of a data science team to analyze large data set · Returns of mid-teens from 2011 to 2017 · Departed firm at end of 2017 to retire from money management business

  • Executive Board Member

    2013 - 2016

    · Company focused on cancer stem cells as targets for antibody therapeutics · Valuation at the time of sale to Abbvie $6.2BN with potential of CVR $4.0BN

  • Portfolio Manager

    2001 - 2010

    · Portfolio Manager covering Global Healthcare Industry · Started out as an analyst covering biotech · Portfolio Manager covering Global Healthcare Industry mid-teens returns · Company dissolved in 2010 with the retirement of Founder, Stanley Druckenmiller

  • Executive Board Member

    2004 - 2007

    · Company focused on developing antibody therapeutics for cancer targets · Valuation at the time of sale to Astellas was $527mm

  • Research associate

    1999 - 2001

    · Research associate covering the biotechnology sector · Initiated on several genomic and antibody companies

Relevant Websites